Big Money Potential In Chelsea Therapeutics [View article]
Northera has an FDA Advisory meeting on February 23rd. I expect a runup to at least $5.50 shr by that date. With positive news from this advisory meeting, we should see $7/shr by March 28's decision date. Northera looks very beneficial to those with Parkinson's, and has potential for many off-label uses. Just look at Japan's usage of the drug over the last 15 years. Thanks Scott for writing up Chelsea!!
Spectrum is another large holding of mine. Thanks for writing it up. It surprises me that shorts attack this company, but it could benefit us with the two NDA filings coming in 2012, increased earnings from Zevalin, continued strong earnings with Fusilev, etc... I think shorts have a hard time dealing with a profitable Bio, and believe bad news has to show up. I hope we continue to prove them wrong. Thanks
Investing In Small Cap Bio-Pharma: Striking It Rich Or Going Bust [View article]
I'm up to 30,000 shares of AIS, and I love the stock more and more each day!! Can't wait to see us hit $4/shr. OK, enough cheerleading, BUT, I do own the shares, and have researched the heck out of AIS. So to us longs, best of financial gains in the coming near future!
3 Biotechs That Were Crushed This Week And Why [View article]
Thank You. Traded in BIO's for many years. Bought BPAX at .44/shr today. Margin calls increase downward trend in first couple days. Looking for a dead cat bounce up on Tuesday. We'll see.
I am 100% in agreement on Chelsea Therapeutics! I don't have to tell you my research, as you more likely know more about the company than me. But I have a large amount of shares, that I predict will see $10/share by mid 2012. Thank You for a overall great article!
Keryx Biopharmaceuticals Could Easily Triple Within the Next Year [View article]
It's 2011, and we're at $4.20/shr. I just listened to the Jan 11, 2011 webcast, and things look better than ever for Keryx. I expect to see $8/shr minimum this year. Other thoughts??
XenoPort: A High Probablity Run-Up Trade [View article]
Great research, and informative! I own Xenoport, and your research added greatly to what I already knew on the company. Looking for positive Phase III data in May, and hope for a spike into the $9's. Thanks again!!
Superb article and analysis!! I've read most of the referred articles, but never put the puzzle together. Thanks so much for your hard work, and I look forward to a prosperous year in Athersys!
Athersys, Inc. Has Blockbuster Potential [View article]
Bio~ Thanks for the great article!! Very informative. Even with all the due diligence I've done on this one, I fee I learned a great deal. I appreciate your research here! MultiStem is very exciting!
Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M. The company cites a change in ordering patterns of Fusilev and an increase in generic competition in its hospital segment for the shortfall, following the recent stabilization of the folate analog market. Shares remain halted AH. [View news story]
No. Not unless this drops to $5/share, and other drugs in their pipeline begin to produce.
Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M. The company cites a change in ordering patterns of Fusilev and an increase in generic competition in its hospital segment for the shortfall, following the recent stabilization of the folate analog market. Shares remain halted AH. [View news story]
Big Money Potential In Chelsea Therapeutics [View article]
Spectrum Pharma: Solid Tech, Solid Fundamentals, Explosive Growth [View article]
Spectrum is another large holding of mine. Thanks for writing it up. It surprises me that shorts attack this company, but it could benefit us with the two NDA filings coming in 2012, increased earnings from Zevalin, continued strong earnings with Fusilev, etc... I think shorts have a hard time dealing with a profitable Bio, and believe bad news has to show up. I hope we continue to prove them wrong.
Thanks
Investing In Small Cap Bio-Pharma: Striking It Rich Or Going Bust [View article]
3 Biotechs That Were Crushed This Week And Why [View article]
Avanir - Closing Short Position [View article]
Keryx Biopharmaceuticals Could Easily Triple Within the Next Year [View article]
XenoPort: A High Probablity Run-Up Trade [View article]
Thanks again!!
Athersys: Valuation [View article]
Athersys, Inc. Has Blockbuster Potential [View article]
Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M. The company cites a change in ordering patterns of Fusilev and an increase in generic competition in its hospital segment for the shortfall, following the recent stabilization of the folate analog market. Shares remain halted AH. [View news story]
Spectrum Pharmaceuticals (SPPI) guides FY13 revenue below Street estimates, now anticipating total revenues in the range of $160M to $180M. Analysts were projecting FY13 revenue to come in at $297M. The company cites a change in ordering patterns of Fusilev and an increase in generic competition in its hospital segment for the shortfall, following the recent stabilization of the folate analog market. Shares remain halted AH. [View news story]
4 Undervalued Stocks: We Like These In An Overbought Stock Market [View article]
Athersys: The Coming Year Will Define MultiStem, Its Adult Stem Cell Product [View article]
The Future Of Zalicus In 2013 [View article]
The Future Of Zalicus In 2013 [View article]